Francois Rochon - Giverny Capital
Holding/activity history for Novo Nordisk A/S (NVO)
← All NVO superinvestors
| Period | Shares | % of Portfolio | Activity | % Change to Portfolio | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026 Q1 | 12,400 | 0.02 | $36.75 | $455,700 | SEC | ||
| 2025 Q4 | 12,400 | 0.02 | $50.88 | $630,912 | SEC | ||
| 2025 Q3 | 12,400 | 0.02 | $55.49 | $688,076 | SEC | ||
| 2025 Q2 | 12,400 | 0.03 | $69.02 | $855,848 | SEC | ||
| 2025 Q1 | 12,400 | 0.03 | $69.44 | $861,056 | SEC | ||
| 2024 Q4 | 12,400 | 0.04 | $86.02 | $1,066,648 | SEC | ||
| 2024 Q3 | 12,400 | 0.06 | $119.07 | $1,476,468 | SEC | ||
| 2024 Q2 | 12,400 | 0.07 | $142.74 | $1,769,976 | SEC | ||
| 2024 Q1 | 12,400 | 0.06 | $128.40 | $1,592,160 | SEC | ||
| 2023 Q4 | 12,400 | 0.06 | $103.45 | $1,282,780 | SEC | ||
| 2023 Q3 | 12,400 | 0.06 | $90.94 | $1,127,656 | SEC | ||
| 2023 Q2 | 12,400 | 0.05 | $80.92 | $1,003,346 | SEC | ||
| 2023 Q1 | 12,400 | 0.06 | $79.57 | $986,668 | SEC | ||
| 2022 Q4 | 12,400 | 0.05 | $67.67 | $839,108 | SEC | ||
| 2022 Q3 | 12,400 | 0.04 | $49.84 | $618,000 | SEC | ||
| 2022 Q2 | 12,400 | 0.05 | $55.73 | $691,000 | SEC | ||
| 2022 Q1 | 12,400 | 0.04 | $55.57 | $689,000 | SEC | ||
| 2021 Q4 | 12,400 | 0.04 | $55.97 | $694,000 | SEC | ||
| 2021 Q3 | 12,400 | 0.04 | $47.99 | $595,000 | SEC | ||
| 2021 Q2 | 12,400 | 0.03 | $41.86 | $519,000 | SEC | ||
| 2021 Q1 | 12,400 | 0.03 | $33.71 | $418,000 | SEC | ||
| 2020 Q4 | 12,400 | 0.03 | $34.92 | $433,000 | SEC | ||
| 2020 Q3 | 12,400 | 0.04 | Buy | 0.04 | $31.64–35.23 · VW $33.86i | $430,000 | SEC |
Price snapshot:
Current price$49.28
Avg. buy price$34.68
+/- since buy42.12%
52-week low$34.58
52-week high$68.49